Dr. Manisha C. Balwani, MD, MS

Dr. Balwani practices at Genetics and Genomic Sciences Department of Mount Sinai in New York, New York.

Dr. Balwani's NPI, 1548362759, was assigned on September 1, 2006. Dr. Balwani graduated from Topiwala National Medical College in 1997. Dr. Balwani holds New York license 002709.

Dr. Balwani's primary practice is Genetics and Genomic Sciences Department of Mount Sinai, at 1428 Madison Ave, New York, NY 10029 in New York County. The practice phone is (212) 241-8717.

Dr. Balwani's primary practice is Genetics and Genomic Sciences Department of Mount Sinai in New York, New York. Dr. Balwani is also affiliated with The Mount Sinai Hospital. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Balwani to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Balwani practices, 2 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Balwani's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Balwani is board certified in clinical genetics by the American Board of Medical Genetics and Genomics. Dr. Balwani is licensed in New York.

CMS data shows 56 Medicare services from Dr. Balwani across 2 procedure codes in 2024, for 67 Medicare patients. Medicare paid $1,222 for them. Every service was in an office.

CMS counts 67 Medicare patients who saw Dr. Balwani in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have high cholesterol, and 58% have high blood pressure. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Balwani's median patient age at 44, with 65% women.

In 2024, Dr. Balwani wrote 19 Medicare Part D claims. 0% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $408,088 in total drug cost. In 2017, CMS named 35 claims across 2 drugs.

Dr. Balwani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Balwani as offering telehealth.

Dmand AI links 79 papers to Dr. Balwani, published from 2010 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Gaucher Disease, Glucosylceramidase and Porphyria, Acute Intermittent. Dr. Balwani has published most often in Mol Genet Metab. Dr. Balwani's most frequent co-authors are Robert J. Desnick, PhD, MD, Karl E. Anderson, MD and Bruce Maozheng Wang, MD.

Dmand AI links Dr. Balwani to 4 clinical trials. Conditions studied include Gaucher Disease, Protoporphyria, Erythropoietic, X-Linked Dominant and Protoporphyria, Erythropoietic. Icahn School of Medicine at Mount Sinai sponsors the most, 2. Open Payments lists research payments to Dr. Balwani that name 2 trials.

CMS Open Payments shows 275 general payments to Dr. Balwani from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Sanofi and Genzyme US Companies paid the most, $102,750. It also lists 15 research payments totaling $8,610 from 2019 to 2021, naming 2 clinical trials.

Dr. Balwani graduated from Topiwala National Medical College in 1997.

Dr. Balwani is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.